Global pet cancer therapeutics marketis expected to reach $432.8 million by 2027Global pet cancer therapeutics marketis expected to reach $432.8 million by 2027. Global pet cancer therapeutics market is valued approximately at $226.25 million in 2020 and is anticipated to grow with a healthy growth rate of about 9.71% over the forecast period 2021-2027. Pet cancer therapeutics deals with the novel anti-cancer drugsthat are used in the cancer treatment and is capableof suppressingeffects of cancerous cells and restricttheir growth in animals such as cats, dogs, etc. The global pet cancer therapeutics marketis being driven by prevalence of several types of cancers in cats and dogs and increase in animal health awareness. Furthermore, there have been different initiatives taken place for research and developmentregarding pet cancer management whichwill provide new opportunities for the global pet cancer therapeutics industry. For instance, according to the American Association for the Advancement of Science, in 2021, a research driven pharmaceutical company named Merck Animal Health has granted $0.1 million to Morris Animal Foundation to support research in animal cancer that would help to advance animal cancer care. Also, in 2017, the University of Queensland received a grant worth $2.5 million from the Australian Cancer Research Foundation (ACRF)for the examination of effects of small doses of anti-cancer drugs in animal as well as human cancers at a cellular level.Such research and development activities related topet cancer management is expected to drive the market by increasing the adoption of pet cancer therapeutics. However,side effects caused by drugs used for the treatment of pet cancersmay impede market growth over the forecast period of 2021-2027.

The regional analysis of the global pet cancer therapeutics market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region across the world in terms of market share due to increasing pet adoption, growth in per capita animal healthcare expenditure, prevalence of different animal diseases and injuries, etc. in the region. Whereas Asia Pacific is anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to growing awareness as well as availability of different pet cancer medicine etc. across the region.

Major market player included in this report are:
AB Science
AdvaVet Inc.
Boehringer Ingelheim GmbH (Merial)
Elanco
ELIAS Animal Health
Karyopharm Therapeutics, Inc.
Rhizen Pharmaceuticals SA
Torigen Pharmaceuticals Inc.
VetDC Inc.
Virbac

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy:
Chemotherapy
Radiation therapy
Immunotherapy
Others
By Animal:
Dogs
Cats
Others
By Application:
Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Pet Cancer Therapeutics Marketin Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors